Evidence map›Paper›PMID 28178039›Full record

ReviewCurrent opinion in hematology2017

Rap1 in endothelial biology.

Magdalena Chrzanowska-Wodnicka

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Divergent Functions of Rap1A and Rap1B in Endothelial Biology and Disease.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Rap1 Brings the A Game to Control Lung Endothelium.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Endothelial cell direct reprogramming: Past, present, and future.Journal of molecular and cellular cardiology · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Magdalena Chrzanowska-WodnickaBlood Research Institute, BloodCenter of Wisconsin, Part of Versiti, Milwaukee, Wisconsin.
Versiti Blood Center of Wisconsin · US

Funding

Rap1 in VEGF signaling in endothelial cellsR01HL111582 · NHLBI · VERSITI WISCONSIN, INC. · PI CHRZANOWSKA, MAGDALENA · 2012 to 2019
$3.3M
NHLBI NIH HHS R01 HL111582
6 · The paper itself

Abstract

purpose of reviewUbiquitously-expressed small GTPase Rap1 is a key modulator of integrin- and cadherin-regulated processes. In endothelium, Rap1 promotes angiogenesis and endothelial barrier function, acting downstream from cAMP-activated Rap1GEF, Epac. Recent in-vivo studies in mouse models have provided more information about the physiological role of Rap1 in vessel development and after birth under normal and pathologic conditions. Important molecular details of dynamic regulation of endothelial barrier are uncovered. RECENT

findingsRap1 is not essential for initial vessel formation but is critical for vessel stabilization, as double knockout of the two Rap1 isoforms leads to hemorrhage and embryonic lethality. After development, Rap1 is not required for endothelial barrier maintenance but is critical for nitric oxide production and endothelial function. Radil and Afadin mediate Rap1 effects on endothelial barrier function by regulating connection with Rho GTPases, actomyosin cytoskeleton, and cell-cell adhesion receptors. SUMMARY: Rap1 is critically required for nitric oxide release and normal endothelial function in vivo. Mechanistic studies lead to a novel paradigm of Rap1 as a critical regulator of endothelial cell shear stress responses and endothelial homeostasis. Increased understanding of molecular mechanisms underlying endothelial barrier regulation may identify novel pharmacological targets for retinopathies and conditions with altered endothelial barrier function or when increased endothelial barrier is desired.

Indexed as

Adherens JunctionsAnimalsBiomarkersCarrier ProteinsEndothelial CellsHumansInflammationMicrofilament ProteinsNeovascularization, PathologicNeovascularization, PhysiologicNitric OxideProtein Bindingrap1 GTP-Binding ProteinsShear StrengthSignal TransductionStress, PhysiologicalafadinBiomarkersCarrier ProteinsMicrofilament ProteinsNitric Oxiderap1 GTP-Binding Proteins

Identifiers

PMID28178039
PMCPMC5920548
OpenAlexW2587805291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.